“Speed without compromise” is a phrase nearly every drug company uses, which is exactly why it has stopped meaning anything.
Alifarc means something specific by it. It is worth being clear about what that is, and what it is not.
What it does not mean
It does not mean cutting corners. We will not negotiate safety standards, rush clinical trials, or treat quality checks as a way to save time. The rules that govern medicine, set by regulators like the MHRA in the UK, BfArM and the EMA in Europe, NAFDAC in Nigeria, and the FDA in the United States, exist for good reason. We are building to work within them, not around them.
What it does mean
Our speed comes from how the company is built, not from anything we skip. Three choices remove delay that has nothing to do with safety:
- We do more of the work ourselves. Most drug companies hand their research and manufacturing to outside firms, and every hand-off between companies costs time and loses knowledge. By keeping more of the work in-house, from research through to manufacturing, we remove those hand-offs.
- We own our own science. When the patents and know-how behind a product are spread across outside vendors, every new programme means slow, costly negotiations. Owning our platform means we don’t pay that toll.
- We built for three countries from the start. Operating across the UK, Germany, and Nigeria was designed in from the beginning rather than added later, so there is far less rework adapting each programme to each country’s rules.
None of these choices touch a single safety or quality standard. They simply remove the friction that slows conventional drug development down. That is what we mean by speed without compromise.
It is, admittedly, harder to fit on a slide than the phrase itself. But it is what the company was built to do.